Prognostic value of 13C-phenylalanine breath test on predicting survival in patients with chronic liver failure

World Journal of Gastroenterology

Volumn 13, Issue 34, 2007, Pages 4579-4585

  Gallardo Wong, I ^a   Morán, Segundo ^a   Rodriguez Leal G ^a   Castaneda Romero B ^a   Mera, R ^b   Poo, J ^c   Uribe, M ^c   Dehesa, M ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Hospital Medica Sur   (Mexico)

Author keywords

13C phenylalanine breath test; Chronic liver failure; Liver cirrhosis; Survival

Indexed keywords

ALBUMIN; BILIRUBIN; CARBON 13; CREATININE; PHENYLALANINE;

ADULT; AGE; AGED; ARTICLE; BLOOD ANALYSIS; BREATH ANALYSIS; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LIVER FAILURE; LIVER FUNCTION; MALE; MULTIVARIATE ANALYSIS; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SCORING SYSTEM; SURVIVAL; UNIVARIATE ANALYSIS;

EID: 34648846471     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i34.4579     Document Type: Article

References (43)

1. National Institutes of Health Consensus Development Conference Statement: liver transplantation-June 20-23, 1983. Hepatology 1984; 4: 107S-110S
2. Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 1987; 7: 660-664
3. Orrego H, Israel Y, Blake JE, Medline A. Assessment of prognostic factors in alcoholic liver disease: toward a global quantitative expression of severity. Hepatology 1983; 3: 896-905
4. Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores-where are we and where should we go? J Hepatol 2004; 41: 344-350
5. Becker M. 13C breath test for measurement of liver function. Gut 1998; 43 Suppl 3: S25-S27
6. Merkel C, Bolognesi M, Finucci GF, Angeli P, Caregaro L, Rondana M, Gatta A. Indocyanine green intrinsic hepatic clearance as a prognostic index of survival in patients with cirrhosis. J Hepatol 1989; 9: 16-22
7. Salerno F, Borroni G, Moser P, Sangiovanni A, Almasio P, Budillon G, Capuano G, Muraca. M, Marchesini G, Bernardi M, Marenco G, Molino G, Rossaro L, Solinas A, Ascione A. Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. A prospective multicenter Italian study. AISF Group for the Study of Liver Transplantation. Associazione Italiana per lo Studio del Fegato. J Hepatol 1996; 25: 474-480
8. Albers I, Hartmann H, Bircher J, Creutzfeldt W. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 1989; 24: 269-276
9. Hehir DJ, Jenkins RL, Bistrian BR, Wagner D, Moldawer LL, Young VR, Blackburn GL. Abnormal phenylalanine hydroxylation and tyrosine oxidation in a patient with acute fulminant liver disease with correction by liver transplantation. Gastroenterology 1985; 89: 659-663
10. Ishii Y, Asai S, Kohno T, Suzuki S. Ishii M, Hosoi I, Fujii M, Iwai S, Ishikawa. K. 13CO2 peak value of L-[1-13]phenylalanine breath test reflects hepatopathy. J Surg Res 1999; 86: 130-135
11. Ishii Y, Suzuki S, Kohno T, Aoki M, Kohno T, Ito A, Takayama T, Asai S. L-[1-13C] phenylalanine breath test reflects histological changes in the liver. J Surg Res 2003; 114: 120-125
12. 13C] Phenylalanine oxidation as a measure of hepatocyte functional capacity in end-stage liver disease. Am J Surg 1997; 173: 270-273; discussion 273-274
13. Heberer M, Talke H, Maier KP, Gerok W. Metabolism of phenylalanine in liver diseases. Klin Wochenschr 1980; 58: 1189-1196
14. Lara Baraque S, Razquin M, Jimenez I, Vazquez A, Gisbert JP, Pajares JM. 13C-phenylalanine and 13C-methacetin breath test to evaluate functional capacity of chronic liver disease. Dig Liver Dis 2000; 32: 226-232
15. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649
16. Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; 72: 573-583
17. Schneider JF, Schoeller DA, Nemchausky B, Boyer JL, Klein P. Validation of 13CO2 breath analysis as a measurement of demethylation of stable isotope labeled aminopyrine in man. Clin Chim Acta 1978; 84: 153-162
18. Kleinbaum GD, Survival Analysis. A Self-Learning Text. New York: Springer, 2000:1-170
19. Collet D. Modelling Survival Data in Medical Research. 2nd ed. Washington DC: Chapman & Hall/CRC, 2003:391
20. Seppo Pynnönen, Department of mathematics and Statistics, University of Vaasa. Detection of Outliers in Regression Analysis by Information Criteria 1992, cited 2004-08-11. Available from: URL: www.uwasa.fi/sjp/
21. Festi D, Capodicasa S, Sandri L, Colaiocco-Ferrante L, Staniscia T, Vitacolonna E, Vestito A, Simoni P, Mazzella G, Portincasa. P, Roda E, Colecchia A. Measurement of hepatic functional mass by means of 13C-methacetin and 13C-phenylalanine breath tests: in chronic liver disease: comparison with Child-Pugh score and serum bile add levels. World J Gastroenterol 2005; 11: 142-148
22. Ishii T, Furube M, Hirano S, Takatori K, lida K, Kajiwara M. Evaluation of 13C-phenylalanine and 13C-tyrosine breath tests for the measurement of hepatocyte functional capacity in patients with liver cirrhosis. Chem Pharm Bull (Tokyo) 2001; 49: 1507-1511
23. Kobayashi T, Imamura. H, Takayama T, Makuuchi M. The role of preoperative phenylalanine breath test in hepatectomy. Hepatogastroenterology 2003; 50: 1124-1127
24. Koeda N, Iwai M, Kato A, Suzuki K. Validity of 13C-phenylalanine breath test to evaluate functional capacity of hepatocyte in patients with liver cirrhosis and acute hepatitis. Aliment Pharmacol Ther 2005; 21: 851-859
25. Ishii Y, Suzuki S, Kohno T, Aoki M, Goto L Kohno T, Ito A, Asai S. Patients with severe liver cirrhosis followed up by L-[1-(13)C] phenylalanine breath test. J Gastroenterol 2003; 38: 1086-1090
26. Kobayashi T, Kubota K, Imamura H, Hasegawa K, Inoue Y, Takayama T, Makuuchi M. Hepatic phenylalanine metabolism measured by the [13C]phenylalanine breath test. Eur J Clin Invest 2001; 31: 356-361
27. Aoki M, Ishii Y, Ito A, Khono T, Takayama T. Phenylalanine breath test as a method to evaluate hepatic dysfunction in obstructive jaundice. J Surg Res 2006; 130: 119-123
28. Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 1987; 7: 660-664
29. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470
30. Said A, Williams J, Holden J. Remington P, Gangnon R, Musat A, Lucey MR. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004; 40: 897-903
31. Saunders JB, Wright N, Lewis KO. Predicting outcome of paracetamol poisoning by use 14C-aminopyrine breath test. Br Med J 1980; 280: 279-280
32. Schneider JF, Baker AL, Haines NW, Hatfield G, Boyer JL. Aminopyrine N-demethylation: a prognostic test of liver function in patients with alcoholic liver disease. Gastroenterology 1980; 79: 1145-1150
33. Merkel C, Bolopesi M, Bellon S, Bianco S, Honisch B, Lampe H, Angeli P, Gatta A. Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. Gut 1992; 33: 836-842
34. Villeneuve JP, Infante-Rivard C, Ampelas M, Pomier-Layrargues G, Huet PM, Marleau D. Prognostic value of the aminopyrine breath test in cirrhotic patients. Hepatology 1986; 6: 928-931
35. Urbain D, Muls V, Thys O, Ham HR. Aminopyrine breath test improves long-term prognostic evaluation in patients with alcoholic cirrhosis in Child classes A and B. J Hepatol 1995; 22: 179-183
36. Tygstrup N. The galactose elimination capacity in relation to clinical and laboratory findings in patients with cirrhosis. Acta Med Scand 1964; 175: 291-300
37. Henderson JM, Kutner W Bain RP. First-order clearance of plasma galactose: the effect of liver disease. Gastroenterology 1982; 83: 1090-1096
38. Merkel C, Gatta A, Zoh M, Bolognesi M, Angeli P, Iervese T, Marchesini G, Ruol A. Prognostic value of galactose elimination capacity, arrunopyrme breath test, and ICG clearance in patients with cirrhosis. Comparison with the Pugh score. Dig Dis Sci 1991; 36: 1197-1203
39. Lewis FW, Rector WG Jr. Caffeine clearance in cirrhosis. The value of simplified determinations of liver metabolic capacity. J Hepatol 1992; 14: 157-162
40. Joeres R, Klinker H, Heusler H, Epping J, Zilly W, Richter E. Influence of smoking on caffeine elimination in healthy volunteers and in patients with alcoholic liver cirrhosis. Hepatology 1988; 8: 575-579
41. Park GJ, Katelaris PH, Jones DB, Seow F, Le Couteur DG, Ngu MC. Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function. Hepatology 2003; 38: 1227-1236
42. Pomier-Layrargues G, Huet PK Infante-Rivard C, Villeneuve JP, Marleau D, Duguay L, Tanguay S, Lavoie P. Prognostic value of indocyanine green and lidocaine kinetics for survival and chronic hepatic encephalopathy in cirrhotic patients following elective end-to-side portacaval shunt. Hepatology 1988; 8: 1506-1510
43. Navasa. M, Garcia-Pagan JC, Bosch J, Rodes J. Prognostic value of hepatic clearance of indocyanine green in patients with liver cirrhosis and hemorrhage of esophageal varices. Med Clin (Barc) 1992; 98: 290-294